SCHEMBL21628358

SCHEMBL21628358

Cc1ccc(CCSN)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.56
CYP2A6 P11509 1/20 0.56
TAAR1 Q96RJ0 1/20 0.56
KCNH2 Q12809 3/20 0.45
AGXT P21549 2/20 0.43
IDO1 P14902 3/20 0.42
HRH3 Q9Y5N1 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
NOS1 P29475 1/20 0.40
RAB9A P51151 1/20 0.40
HIF1A Q16665 1/20 0.40
IGF1R P08069 1/20 0.39
ALOX15 P16050 1/20 0.39
BLM P54132 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14346666 0.78 CYP1A2 (0.52) CYP1A2CYP2A6TAAR1KCNH2AGXT
SCHEMBL19036563 0.77 CYP1A2 (0.56) CYP1A2CYP2A6TAAR1IDO1TDP1
SCHEMBL31398273 0.76 TAAR1 (0.56) CYP2A6TAAR1IDO1NPC1CYP3A4
SCHEMBL15384438 0.76 ESR1 (0.59) TAAR1IDO1TDP1L3MBTL1NPC1
SCHEMBL11086271 0.76 CYP1A2 (0.50) CYP1A2CYP2A6TAAR1KCNH2AGXT
SCHEMBL143961 0.76 CYP1A2 (0.68) CYP1A2CYP2A6TAAR1KCNH2AGXT
SCHEMBL11288839 0.76 CYP1A2 (0.68) CYP1A2CYP2A6TAAR1KCNH2AGXT
SCHEMBL22101172 0.76 TAAR1 (0.61) TAAR1AGXTIDO1ALDH1A1
SCHEMBL2468970 0.75 IDO1 (0.56) CYP1A2CYP2A6TAAR1AGXTIDO1
SCHEMBL14702015 0.74 CYP1A2 (0.48) CYP1A2CYP2A6TAAR1KCNH2AGXT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11078188-B2 Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2021-08-03 US disclosed
US-20200031802-A1 DIHYDROQUINOXALINE BROMODOMAIN RECOGNITION PROTEIN INHIBITOR, PREPARATION METHOD AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200031802-A1 DIHYDROQUINOXALINE BROMODOMAIN RECOGNITION PROTEIN INHIBITOR, PREPARATION METHOD AND USE THEREOF BRD4, BRPF3, BRD1 CYP1A2 3910/4885CYP2A6 2732/4885TAAR1 3307/4885
US-11078188-B2 Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof BRD4, BRPF3, BRD1 CYP1A2 3910/4885CYP2A6 2732/4885TAAR1 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.